The future of COVID innovations

This is a bonus edition of PharmaVoice’s daily newsletter. Today we’re exploring how medical advances during the COVID-19 pandemic are being applied to new health challenges. Sign up here to receive insights on the biggest trends and voices in the life sciences industry in your inbox every morning.?

If crowded Memorial Day airport lines were any indication, life is finally returning back to its pre-pandemic rhythm for most Americans. In fact, a recent Axios-Ipsos poll found that 62% of Americans now believe the COVID-19 pandemic is over, compared to just 46% of respondents in February. And who could blame them??

In mid-May, U.S. COVID-19 hospitalization rates — one of the few metrics still being monitored by public health agencies —? fell below 9,000 for the first time since the summer of 2020. And earlier in the month, the U.S. ended its COVID-19 public health emergency and national state of emergency orders. While the WHO has yet to declare an end to the pandemic, in May it also said the virus no longer constituted “a public health emergency or international concern.”?

At the same time, many are still feeling the debilitating symptoms of long COVID-19. And public health experts, including WHO director-general Dr. Tedros Adhanom Ghebreyesus, have warned that another, potentially deadlier, pandemic could be lurking around the corner.?

In response, many scientists are digging through the groundbreaking research conducted during the height of the pandemic and pinpointing the innovative techniques that rose to the top.?

From monoclonal antibodies to decentralized clinical trials, here’s a look at how researchers are using pandemic-era approaches to solve public health challenges.

Years into the pandemic, only a handful of clinical trials are targeting long COVID — here’s one of them

Scientists are testing Pfizer’s Paxlovid on long-COVID symptoms and their efforts could provide clues for other conditions.

The post-COVID outlook for decentralized clinical trials

The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward?

He helped launch the Pfizer COVID vaccine — now this startup CEO is hunting a lingering pandemic foe

All of the COVID-19 mAbs have been pulled from the market. But Dave Hering, CEO of Invivyd, hopes?to change that.

The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.

Moderna’s next vax target? A little-known cause of birth defects

How the mRNA-based biotech is developing what could be the first-ever prophylactic for a devastating virus.

This is just a sampling of PharmaVoice’s coverage. For more insights into the biggest trends and voices swaying the life sciences industry, be sure to check out our daily newsletter.